119 related articles for article (PubMed ID: 25356939)
1. The diagnostic utility of combination of HMGA2 and IMP3 qRT-PCR testing in thyroid neoplasms.
Jin L; Lloyd RV; Henry MR; Erickson LA; Sebo TJ; Rumilla KM; Zhang J
Appl Immunohistochem Mol Morphol; 2015 Jan; 23(1):36-43. PubMed ID: 25356939
[TBL] [Abstract][Full Text] [Related]
2. HMGA2 expression analysis in cytological and paraffin-embedded tissue specimens of thyroid tumors by relative quantitative RT-PCR.
Jin L; Lloyd RV; Nassar A; Lappinga PJ; Sebo TJ; Swartz K; Seys AR; Erickson-Johnson MR; Roth CW; Evers BR; Oliveira AM; Zhang J
Diagn Mol Pathol; 2011 Jun; 20(2):71-80. PubMed ID: 21532495
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of IMP3 expression in thyroid neoplasms: a quantitative RT-PCR study.
Jin L; Seys AR; Zhang S; Erickson-Johnson MR; Roth CW; Evers BR; Oliveira AM; Lloyd RV
Diagn Mol Pathol; 2010 Jun; 19(2):63-9. PubMed ID: 20502182
[TBL] [Abstract][Full Text] [Related]
4. HMGA2 Gene Expression in Fine-needle Aspiration Samples of Thyroid Nodules as a Marker for Preoperative Diagnosis of Thyroid Cancer.
Šamija I; Mateša N; Kožaj S; Majstorović I; Bolanča A; Kusić Z
Appl Immunohistochem Mol Morphol; 2019 Jul; 27(6):471-476. PubMed ID: 29406334
[TBL] [Abstract][Full Text] [Related]
5. Combined quantitation of HMGA2 mRNA, microRNAs, and mitochondrial-DNA content enables the identification and typing of thyroid tumors in fine-needle aspiration smears.
Titov SE; Ivanov MK; Demenkov PS; Katanyan GA; Kozorezova ES; Malek AV; Veryaskina YA; Zhimulev IF
BMC Cancer; 2019 Oct; 19(1):1010. PubMed ID: 31660895
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of HMGA2 in thyroid carcinomas: a novel molecular marker to distinguish between benign and malignant follicular neoplasias.
Belge G; Meyer A; Klemke M; Burchardt K; Stern C; Wosniok W; Loeschke S; Bullerdiek J
Genes Chromosomes Cancer; 2008 Jan; 47(1):56-63. PubMed ID: 17943974
[TBL] [Abstract][Full Text] [Related]
7. Three-gene molecular diagnostic model for thyroid cancer.
Prasad NB; Kowalski J; Tsai HL; Talbot K; Somervell H; Kouniavsky G; Wang Y; Dackiw AP; Westra WH; Clark DP; Libutti SK; Umbricht CB; Zeiger MA
Thyroid; 2012 Mar; 22(3):275-84. PubMed ID: 22280184
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors.
Slosar M; Vohra P; Prasad M; Fischer A; Quinlan R; Khan A
Endocr Pathol; 2009; 20(3):149-57. PubMed ID: 19449140
[TBL] [Abstract][Full Text] [Related]
9. Impact of specific patterns on the sensitivity for follicular and Hurthle cell carcinoma in thyroid fine-needle aspiration.
Renshaw AA; Gould EW
Cancer Cytopathol; 2016 Oct; 124(10):729-736. PubMed ID: 27322887
[TBL] [Abstract][Full Text] [Related]
10. Allele-specific PCR with competitive probe blocking for sensitive and specific detection of BRAF V600E in thyroid fine-needle aspiration specimens.
Smith GD; Zhou L; Rowe LR; Jarboe EA; Collins BT; Bentz JS; Wittwer CT; Chadwick BE
Acta Cytol; 2011; 55(6):576-83. PubMed ID: 22156469
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms.
Kebebew E; Peng M; Reiff E; McMillan A
Cancer; 2006 Jun; 106(12):2592-7. PubMed ID: 16688775
[TBL] [Abstract][Full Text] [Related]
12. HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules.
Lappinga PJ; Kip NS; Jin L; Lloyd RV; Henry MR; Zhang J; Nassar A
Cancer Cytopathol; 2010 Oct; 118(5):287-97. PubMed ID: 20597139
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of IMP3 and p53 expression in endoscopic ultrasound-guided fine needle aspiration and resected specimens of pancreatic diseases.
Senoo J; Mikata R; Kishimoto T; Hayashi M; Kusakabe Y; Yasui S; Yamato M; Ohyama H; Sugiyama H; Tsuyuguchi T; Yoshitomi H; Ohtsuka M; Maeda J; Ota S; Nakatani Y; Kato N
Pancreatology; 2018 Mar; 18(2):176-183. PubMed ID: 29305088
[TBL] [Abstract][Full Text] [Related]
14. IMP3 RNP safe houses prevent miRNA-directed HMGA2 mRNA decay in cancer and development.
Jønson L; Christiansen J; Hansen TVO; Vikeså J; Yamamoto Y; Nielsen FC
Cell Rep; 2014 Apr; 7(2):539-551. PubMed ID: 24703842
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of genetic biomarkers for distinguishing benign from malignant thyroid neoplasms.
Nagar S; Ahmed S; Peeples C; Urban N; Boura J; Thibodeau B; Akervall J; Wilson G; Long G; Czako P
Am J Surg; 2014 Apr; 207(4):596-601. PubMed ID: 24713092
[TBL] [Abstract][Full Text] [Related]
16. A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration.
Keutgen XM; Filicori F; Crowley MJ; Wang Y; Scognamiglio T; Hoda R; Buitrago D; Cooper D; Zeiger MA; Zarnegar R; Elemento O; Fahey TJ
Clin Cancer Res; 2012 Apr; 18(7):2032-8. PubMed ID: 22351693
[TBL] [Abstract][Full Text] [Related]
17. Sonographically suspicious thyroid nodules with initially benign cytologic results: the role of a core needle biopsy.
Ha EJ; Baek JH; Lee JH; Song DE; Kim JK; Shong YK; Hong SJ
Thyroid; 2013 Jun; 23(6):703-8. PubMed ID: 23544697
[TBL] [Abstract][Full Text] [Related]
18. Imp3 expression in benign and malignant thyroid tumors and hyperplastic nodules.
Kulaçoğlu S; Erkılınç G
Balkan Med J; 2015 Jan; 32(1):30-7. PubMed ID: 25759769
[TBL] [Abstract][Full Text] [Related]
19. Significance of IMP3, nucleophosmin, and Ki-67 expression in papillary thyroid carcinoma.
Yorukoglu A; Yalcin N; Avci A; Cakalagaoglu F; Yaylali G; Akin F; Haciyanli M; Ozden A
Int J Surg Pathol; 2015 Feb; 23(1):5-12. PubMed ID: 25389240
[TBL] [Abstract][Full Text] [Related]
20. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
